Imjudo & Imfinzi PMS

Study identifier:D419CR00029

ClinicalTrials.gov identifier:NCT06544629

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Imjudo & Imfinzi Post-Marketing Surveillance

Medical condition

Hepatocellular Carcinoma

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Estimated Enrollment

246

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 01 Apr 2025

Estimated Primary Completion Date: 28 Feb 2029

Estimated Study Completion Date: 28 Feb 2029

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2025 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]